Jubilant Life Sciences Ltd (JLL), an integrated pharmaceutical industry player and the largest custom research and manufacturing services (CRAMS) company in India, clocked a 53% year-on-year increase in net profit at Rs 77 crore for the first quarter ended June.
During the quarter, income from operations stood at Rs 948 crore, up 16%, compared to the same quarter in the previous year. The international business from 75 countries contributed 69% to net sales at Rs 653 crore.
Sales from regulated markets of USA, Canada, Europe and Japan stood at Rs 522 crore and amounted to 55% of the net sales.
Sales from Europe and Japan regions grew 50% during the quarter as compared to the same period of the previous fiscal, followed by 16% growth in emerging markets.
Commenting on the company's performance, Shyam S Bhartia, chairman and managing director and Hari S Bhartia, co-chairman and managing director, Jubilant Life Sciences said: "Our products business teams have performed well with a clear objective of aggressive sales growth, innovation led product launches, expansion in high growth geographies and increased vertical integration. Service business teams have taken focussed margin improvement initiatives to substantially increase the profitability."
The company has been ranked sixth among the top 10 global contract manufacturing and services outsourcing players of pharmaceutical industry by the United Nations Conference on Trade and Development World Investment Report 2011, released recently.